Oncology Company Announces FDA Clearance of New Solid Tumor Treatment
stockregion.app
FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors.
Oncology Company Announces FDA Clearance of New Solid Tumor Treatment
Oncology Company Announces FDA Clearance of…
Oncology Company Announces FDA Clearance of New Solid Tumor Treatment
FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors.